Related Experiment Videos
Delafloxacin: design, development and potential place in therapy
Francisco Javier Candel1, Marina Peñuelas1
1Department of Clinical Microbiology and Infectious Diseases, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Universidad Complutense, Madrid, Spain.
Drug Design, Development and Therapy
|March 31, 2017
Summary
Delafloxacin (DLX) is a promising new fluoroquinolone demonstrating potent activity against resistant bacteria like MRSA. Its unique properties offer a potential new treatment option for skin, respiratory, and other infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Delafloxacin (DLX) is an investigational fluoroquinolone antibiotic.
- It exhibits broad-spectrum antimicrobial activity.
- DLX shows efficacy against common pathogens in skin and respiratory infections.
Purpose of the Study:
- To provide a comprehensive analysis of delafloxacin.
- To review its chemical structure, in vitro and in vivo activity.
- To discuss its clinical trial data and potential therapeutic role.
Main Methods:
- Literature review of delafloxacin's properties and clinical data.
- Analysis of in vitro and in vivo study results.
- Evaluation of pharmacokinetic data and activity in acidic environments.
Main Results:
- DLX demonstrates significant in vitro and in vivo activity against key pathogens.
- It is effective against fluoroquinolone-resistant strains, including MRSA.
- Clinical trials show promise for DLX in treating specific infections.
Conclusions:
- Delafloxacin presents a viable therapeutic option for skin/soft tissue and respiratory tract infections.
- Its pharmacokinetic profile and activity in acidic conditions are advantageous.
- DLX warrants consideration in the evolving antimicrobial landscape.